Allogene Therapeutics, Inc. (ALLO) › Capital ExpendituresAllogene Therapeutics, Inc. (ALLO) — Capital ExpendituresAnnual figures by fiscal year, from SEC filings.2018: $3.23M2019: $50.79M2020: $65.96M2021: $21.45M2022: $5.19M2023: $1.52M2024: $694.0K2025: $386.0K$386.0K2018Capital Expenditures (USD)2025Fiscal YearCapital ExpendituresChange YoY2025$386.0K-44.4%2024$694.0K-54.2%2023$1.52M-70.8%2022$5.19M-75.8%2021$21.45M-67.5%2020$65.96M+29.9%2019$50.79M+1470.5%2018$3.23M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowShares OutstandingDividends Per Share